drugset / Trial / NCT07601516

Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China

NCT07601516

Phase 4 Completed 50 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China. The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China.

Timeline

Start
2024-02-02
Primary completion
2025-10-24
Completion
2025-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Deutetrabenazine Unknown